Evidence map›Paper›PMID 34501647›Full record

ArticleInternational journal of environmental research and public health2021

Potential Protection of Pre-Existent Antibodies to Human Coronavirus 229E on COVID-19 Severity.

Oscar Guzmán-Martínez, Kathia Guardado, Miguel Varela-Cardoso, Alejandro Trujillo-Rivera, Iván Gómez-Ñañez, María Cristina Ortiz-León, Rafaela Espinosa, Celso Ramos, Julio Isael Pérez-Carreón, Delia Vanesa López-Guerrero and 6 more

Open access · goldAbstract read
In one paragraph

Article in International journal of environmental research and public health, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 6 institutions in 1 country.

Oscar Guzmán-MartínezInstituto de Salud Pública, Universidad Veracruzana, Xalapa 91190, Mexico.
Kathia GuardadoInstituto de Salud Pública, Universidad Veracruzana, Xalapa 91190, Mexico.
Miguel Varela-CardosoFacultad de Medicina, Universidad Veracruzana, Ciudad Mendoza 94740, Mexico.ORCID 0000-0002-1162-384X
Alejandro Trujillo-RiveraCentro de Alta Especialidad "Dr. Rafael Lucio", Servicio Medicina Interna, Xalapa 91020, Mexico.ORCID 0000-0003-3437-2622
Iván Gómez-ÑañezInstituto de Salud Pública, Universidad Veracruzana, Xalapa 91190, Mexico.
María Cristina Ortiz-LeónInstituto de Salud Pública, Universidad Veracruzana, Xalapa 91190, Mexico.ORCID 0000-0003-4953-5076
Rafaela EspinosaInstituto de Biotecnología, Universidad Nacional Autónoma de México, Cuernavaca 62210, Mexico.
Celso RamosCentro de Investigación Sobre Enfermedades Infecciosas, Instituto Nacional de Salud Pública, Cuernavaca 62100, Mexico.
Julio Isael Pérez-CarreónInstituto Nacional de Medicina Genómica, Ciudad de México 14610, Mexico.ORCID 0000-0001-9284-7775
Delia Vanesa López-GuerreroFacultad de Nutrición, Universidad Autónoma del Estado de Morelos, Cuernavaca 62350, Mexico.ORCID 0000-0002-2920-845X
Clara Luz SampieriInstituto de Salud Pública, Universidad Veracruzana, Xalapa 91190, Mexico.
Adrián Baruch Alanís-GarcíaJurisdicción Sanitaria No. VII, Servicios de Salud, Orizaba 94300, Mexico.
Fausto Rojas-DuránInstituto de Investigaciones Cerebrales, Universidad Veracruzana, Xalapa 91190, Mexico.
Roberto Zenteno-CuevasInstituto de Salud Pública, Universidad Veracruzana, Xalapa 91190, Mexico.
Michelle GutiérrezInstituto de Biotecnología, Universidad Nacional Autónoma de México, Cuernavaca 62210, Mexico.
Hilda MonteroInstituto de Salud Pública, Universidad Veracruzana, Xalapa 91190, Mexico.ORCID 0000-0001-8090-4103
Universidad Veracruzana · MXUniversidad Nacional Autónoma de México · MXInstituto Nacional de Salud Pública · MXNational Institute of Genomic Medicine · MXSecretaria de Salud · MXUniversidad Autónoma del Estado de Morelos · MX

Funding

Consejo Nacional de Ciencia y Tecnología 312487
6 · The paper itself

Abstract

The causes of the broad spectrum of severity in COVID-19 are unknown. A protective effect through humoral immunity from previous infections by viruses of the SARS-CoV-2 family could explain a mild form of this disease. This study aimed to address whether the presence of antibodies against human seasonal coronaviruses (HCoVs) could prevent severe manifestations of COVID-19. A cross-sectional study was carried out in 165 participants. The presence of pre-existent antibodies against the seasonal HCoV-OC43, HCoV-HKU1, HCoV-229E, and HCoV-NL63 were detected. From all of the seasonal HCoVs studied, it was only found that being seropositive to HCoV-229E presented an association (

Indexed as

Coronavirus 229E, HumanCOVID-19Antibodies, ViralCross-Sectional StudiesFemaleHumansSARS-CoV-2Antibodies, ViralantibodiesCOVID-19human coronavirusSARS-CoV-2seroprotection

Identifiers

PMID34501647
PMCPMC8430483
OpenAlexW3197326770

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.